STAT

Signaling concern over industry funding, Congress presses for transparency at groups supporting NIH, CDC

The NIH and CDC have hit a series of ethical snags in recent years, with questions about whether work funded by nonprofit groups has come with too many conditions attached.…
Aerial view of the Clinical Center on the NIH campus.

WASHINGTON — The National Institutes of Health has hit a series of ethical snags in recent years, with questions about whether work funded by nonprofit groups has come with too many conditions attached or otherwise failed to meet certain ethical standards.

Congress has taken notice.

In what amounts to a written warning from Capitol Hill, a House committee last week included language in a spending agreement that emphasizes existing requirements on funding from the Foundation for

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks